Pastorelli et al. confirmed the observation of elevated levels of IL1RL1 and IL33 in the serum and mucosa of IBD patients; they also showed that anti-TNF decreased IL1RL1 isoform A levels and increased the soluble isoform making more decoy receptor available in order to sequester IL33 and reduce the inflammation [66]. Here, IL33 is linked to inflammatory bowel disease.